
COVID-OUT: early metformin cut long Covid risk by 42% in a large randomized trial
The COVID-OUT phase 3 trial (>1000 mostly non-diabetic outpatients) found metformin lowered long Covid incidence by 42% relative to placebo, and by 63% when started within 4 days of symptoms. Ivermectin and fluvoxamine did not prevent long Covid.
